Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

PBYI $229.06 20.3950 +9.77%
EPZM $19.40 1.0399 +5.66%
XNCR $17.21 0.9149 +5.61%
ISIS $62.89 3.3401 +5.61%
AGEN $4.14 0.2151 +5.48%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

IMGN $5.62 -5.2299 -48.20%
GTXI $0.90 -0.0694 -7.15%
PARD $0.16 -0.0100 -5.88%
GLYC $8.61 -0.4500 -4.97%
TLOG $4.80 -0.2500 -4.95%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Next > | Last >>

Exercise Eases Arthralgia Caused by Aromatase Inhibitors

(Physician's Briefing/HealthDay News) Dec 10, 2014 - Exercise helps relieve aromatase inhibitor (AI)-induced pain in breast cancer survivors, according to research published online Dec. 1 in the Journal of Clinical Oncology.
read article 



New Methods Explored to Localize Nonpalpable Breast Lesions

(Medscape Medical News) Dec 11, 2014 - New and better methods are needed for localizing nonpalpable breast lesions at the time of surgical excision, according to two researchers who presented preliminary data on alternative methods here at San Antonio Breast Cancer Symposium (SABCS) 2014.
read article (free registration required) 



Pathway That Degrades Holiday Turkey Fuels Metastasis of Triple Negative Breast Cancer

(UCCC/In the Clinic blog) Dec 10, 2014 - A University of Colorado Cancer Center study being presented at the San Antonio Breast Cancer Symposium shows that triple negative breast cancer cells process tryptophan to promote survival while traveling through the body in order to seed new tumor sites.
read article 



3 San Antonio Studies Target Androgen in Breast Cancer

(UCCC/In the Lab blog) Dec 11, 2014 - Three studies presented by University of Colorado Cancer Center researchers at the San Antonio Breast Cancer Symposium 2014 demonstrate the effects of blocking androgen receptors in breast cancer.
read article 



Breastfeeding Can Cut Cancer by Up to One Fifth

(The Telegraph [UK]) Dec 11, 2014 - Breastfeeding could cut the chance of breast cancer by up to one fifth, a major international study has found.
read article 



Combination of Carboplatin and Chemotherapy Improves Outcomes For Triple-Negative Breast Cancer Patients

(Dana-Farber) Dec 11, 2014 - In a clinical trial involving women with triple-negative breast cancer, patients who received the drugs carboplatin and/or bevacizumab in combination with standard chemotherapy prior to surgery were more likely to have their tumors disappear entirely from the breast, according to data presented by investigators during the 2014 San Antonio Breast Cancer Symposium.
read press release 



Capecitabine Monotherapy Does Not Improve Survival in Elderly Patients With Early-Stage Breast Cancer

(AACR) Dec 11, 2014 - In elderly breast cancer patients with moderate- to high-risk early-stage disease for whom standard chemotherapy is too toxic, the chemotherapy capecitabine, which causes fewer side effects than the standard chemotherapy agents, did not improve outcomes when tested as monotherapy, according to data from the phase III ICE trial presented at the 2014 San Antonio Breast Cancer Symposium, held Dec. 9–13.
read press release 



Adding Ovarian Suppression to Tamoxifen Reduced Recurrence For Some Women With Premenopausal Breast Cancer

(AACR) Dec 11, 2014 - Among premenopausal women with early-stage, hormone receptor-positive breast cancer, adding ovarian suppression to tamoxifen reduced breast cancer recurrence for those who had previously received chemotherapy and remained premenopausal, according to data from the randomized, phase III suppression of ovarian function trial (SOFT) presented at the 2014 San Antonio Breast Cancer Symposium, held Dec. 9–13.
read press release 



IBIS-I Trial Finds Tamoxifen Lowered Breast Cancer Rates Among High-Risk Women

(AACR) Dec 11, 2014 - After a median of 16 years of following women at high risk for breast cancer, the International Breast Cancer Intervention Study-I (IBIS-I) trial found that tamoxifen significantly decreased the incidence of all breast cancers, according to data presented at the 2014 San Antonio Breast Cancer Symposium, held Dec. 9–13.
read press release 



New Treatment Shows Promise in Younger Breast Cancer Patients: Study

(Philadelphia Inquirer/HealthDay News) Dec 11, 2014 - A treatment known as ovarian suppression used along with an anti-estrogen drug normally given to older women appears to greatly reduce the risk of breast cancer recurrence in some younger women, new research suggests.
read article 



Breast Cancer Prevention Drug Gives Lasting Protection, Study Finds

(Los Angeles Times/Science Now) Dec 11, 2014 - Taking the cancer drug tamoxifen for five years drives down the incidence of breast cancer in women at high risk for the disease by close to 30%, researchers have found.
read article (free registration required) 



What's Intriguing and Concerning About Early Results For Keytruda in Breast Cancer

(Forbes) Dec 11, 2014 - At first glance, it’s hard to get excited about the preliminary results of an early phase trial study of pembrolizumab (Keytruda, MK-3475) in women with triple-negative breast cancer (TNBC).
read article 



Phase III Results From German Breast Group (GBG) Demonstrates Superior Activity in High Risk Early Breast Cancer For Nab-Paclitaxel (ABRAXANE®) VS. Solvent-Based Paclitaxel

(Yahoo! Finance) Dec 11, 2014 - Phase III results demonstrate significant pCR (pathological complete response) for nab-paclitaxel in neoadjuvant breast cancer.
read article 



Novel Approach for Estrogen-receptor-positive Breast Cancer Reported

(Loyola Health Sciences) Dec 10, 2014 - Loyola researchers and collaborators have reported promising results from a novel therapeutic approach for women with estrogen-receptor-positive breast cancer.
read press release 



Gilead Sued Over 'Exorbitant' Hepatitis C Drug Prices

(Reuters) Dec 10, 2014 - Philadelphia's transportation authority has filed a class action lawsuit accusing Gilead Sciences Inc of charging "exorbitant" prices for its blockbuster hepatitis C drug Sovaldi.
read article 



Chemo Telepharmacy Project Takes Top Award at ASHP

(Medscape Medical News) Dec 10, 2014 - A telepharmacy pilot project allowing licensed pharmacists to supervise the mixing of chemotherapy by pharmacy technicians in areas up to 90 minutes from a prominent cancer center has received national recognition.
read article (free registration required) 



Higher-Earning Physicians Order More Services

(Medscape Medical News) Dec 10, 2014 - CMS data show wide variation in physician payments based on services provided, not the number of patients treated.
read article (free registration required) 



Zydus Cadila Launches Biosimilar of AbbVie's Humira in India

(The Economic Times [New Delhi, India]) Dec 9, 2014 - Drug firm Zydus Cadila today launched biosimilar of Adalimumab, used for treatment of auto immune disorders, at a price much lower than the innovator drug in India.
read article 



Biotechs and Generic Drug Makers Compromise on Biosimilar Lobbying

(Wall Street Journal/Pharmalot blog) Dec 10, 2014 - Biotech and generic drug makers reached a compromise on lobbying state legislature for biosimilar substitution.
read article (paid subscription required) 



Katmai Oncology Group Joins Seattle Cancer Care Alliance Affiliate Network

(Seattle Cancer Care Alliance) Dec 9, 2014 - Katmai Oncology Group has joined the Seattle Cancer Care Alliance (SCCA) Network to become its eleventh affiliate in the greater Northwest. The affiliation will expand local access to cancer treatment options and help foster advances in cancer care.
read press release 



Mistaken Identities Plague Lab Work With Human Cells

(NPR/Shots blog) Dec 9, 2014 - A line of immortal cells, supposedly from a breast cancer patient, turned out to be from a type of skin cancer. The mix-up wasn't discovered until experiments around the world had been contaminated.
read article 



Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (nivolumab) and Mogamulizumab in Advanced Solid Tumors

(Bristol-Myers Squibb) Dec 10, 2014 - Ono Pharmaceutical Co.,Ltd., Bristol-Myers Squibb Company and Kyowa Hakko Kirin Co., Ltd. announced today the companies have entered into a clinical trial collaboration agreement to conduct a Phase 1 combination study with Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor, and mogamulizumab, an anti-CCR4 antibody.
read corporate press release 



Immunovaccine Receives FDA Fast Track Designation for DPX-Survivac for Treatment of Ovarian Cancer

(Immunovaccine) Dec 10, 2014 - Immunovaccine Inc. today announced that DPX-Survivac, the Company's lead cancer vaccine candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) as maintenance therapy in subjects with advanced ovarian, fallopian tube, and peritoneal cancer who have no measureable disease following surgery and front-line platinum/taxane chemotherapy to improve their progression-free survival.
read corporate press release 



FDA Approves Gardasil 9 for Prevention of Certain Cancers Caused by Five Additional Types of HPV

(FDA.gov) Dec 10, 2014 - The U.S. Food and Drug Administration today approved Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for the prevention of certain diseases caused by nine types of Human Papillomavirus (HPV). Covering nine HPV types, five more HPV types than Gardasil (previously approved by the FDA), Gardasil 9 has the potential to prevent approximately 90 percent of cervical, vulvar, vaginal and anal cancers.
read press release 



AACR Mourns Loss of Past-President Lee Wattenberg, “Father of Chemoprevention”

(AACR) Dec 10, 2014 - The cancer research community mourns the loss of Lee W. Wattenberg, MD, emeritus professor of laboratory medicine and pathology at the University of Minnesota Masonic Cancer Center in Minneapolis, who died Dec. 9, 2014, at the age of 92.
read press release